Publications by authors named "Qijie Ran"

Objectives: Circular RNA_0003489 (Circ_0003489) promotes multiple myeloma (MM) progression and bortezomib resistance in MM cells, while its potential as a biomarker in newly diagnosed MM (NDMM) patients is unclear. Thus, this study aimed to investigate the association of circ_0003489 expression with treatment response and survival in NDMM patients who received bortezomib-based induction therapy.

Methods: Bone marrow (BM) specimens from 85 NDMM patients at diagnosis or before treatment and from 15 donor controls during BM examination were retrieved in this retrospective study.

View Article and Find Full Text PDF

Background: Targeted protein degradation of neosubstrates plays a crucial role in hematological cancer treatment involving immunomodulatory imide drugs (IMiDs) therapy. Nevertheless, the persistence of inevitable drug resistance and hematological toxicities represents a significant obstacle to their clinical effectiveness.

Methods: Phenotypic profiling of a small molecule compounds library in multiple hematological cancer cell lines was conducted to screen for hit degraders.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma is a type of cancer that doesn’t show clear symptoms early on but can cause serious problems in bones later.
  • Researchers found that a small molecule called miR-23 is involved in controlling another protein, uPA, which affects the cancer's severity.
  • Increasing miR-23 levels can help lower uPA levels and stop the cancer cells from spreading, which might help in creating better treatments for this disease.
View Article and Find Full Text PDF

Objective: The anti-tumor effect of polo-like kinase 4 (PLK4) inhibitor has been explored in several neoplasms, while its synergy with bortezomib in multiple myeloma (MM) remains elusive. Hence, the present study aimed to investigate the effect of PLK4 inhibitor on the sensitivity of MM to bortezomib treatment and its underlying mechanism.

Methods: MM cell lines (RPMI-8226 and U266) were cultured in different concentrations of CFI-400945 (PLK4 inhibitor), bortezomib, or their combination.

View Article and Find Full Text PDF

The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent risk factor for in-hospital death from COVID-19 in persons <65 years (hazard ratio [HR] = 2.

View Article and Find Full Text PDF

The gene expression for interleukin-2 receptor subunit alpha (CD25/IL2RA) is frequently altered in adults with acute myeloid leukemia (AML). Increasing evidence indicates that the elevated expression of CD25 may be correlated with poor survival for AML patients. Thus, we performed this meta-analysis to further evaluate the prognostic value of elevated CD25 in AML.

View Article and Find Full Text PDF

We studied 1859 subjects with confirmed COVID-19 from seven centers in Wuhan 1651 of whom recovered and 208 died. We interrogated diverse covariates for correlations with risk of death from COVID-19. In multi-variable Cox regression analyses increased hazards of in-hospital death were associated with several admission covariates: (1) older age (HR = 1.

View Article and Find Full Text PDF

We studied admission and dynamic demographic, hematological and biochemical co-variates in 1449 hospitalized subjects with coronavirus infectious disease-2019 (COVID-19) in five hospitals in Wuhan, Hubei province, China. We identified two admission co-variates: age (Odds Ratio [OR] = 1.18, 95% Confidence Interval [CI] [1.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Qijie Ran"

  • - Recent research by Qijie Ran focuses on the progression and treatment of multiple myeloma (MM), particularly examining the role of circular RNA_0003489 as a biomarker and its association with treatment response and survival in newly diagnosed patients receiving bortezomib-based induction therapy.
  • - The author has also explored innovative strategies in hematological cancer treatment, developing potent molecular glue degraders targeting multiple neosubstrates to combat drug resistance and hematological toxicities, highlighting advances in personalized oncology.
  • - Additionally, Ran's studies include understanding the hypermethylation of miR-23 and its effects on uPA expression linked to MM cell proliferation, as well as the prognostic implications of CD25 expression in acute myeloid leukemia, within the broader context of cancer impacts during the COVID-19 pandemic.